Atlantic International Corp. (ATLN) is a publicly traded company in the Healthcare — Medical - Pharmaceuticals industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Based in Billerica, Massachusetts, and established in 2013, Atlantic International Corp. (which operated as SeqLL Inc. until its name change in June 2024) underwent a significant corporate change on June 18, 2024, when it was acquired by Lyneer Investments, LLC, via a reverse merger. The company operates within the life sciences sector, providing specialized instrumentation and research services.
Analysis Summary
Atlantic International Corp. reported revenue of $435.9M in the most recent fiscal year, growing at a 5-year CAGR of 321.0%.
Trailing-twelve-month margins: gross margin 8.6%, operating margin -7.8%, net margin -19.4%.
At the current price of $0.90, ATLN has negative trailing earnings (P/E not meaningful) and an ROE of -83.20%. Market capitalisation stands at $73M.
Balance sheet quality for ATLN: current ratio of 0.7, net debt of $87.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.90 |
| Market Cap | $73M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 7.10 |
| EV / EBITDA | -3.31 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -8319.60% |
| Return on Invested Capital | -16.39% |
| Return on Assets | -16.06% |
| Gross Margin | 8.58% |
| Operating Margin | -7.80% |
| Net Margin | -19.39% |
Financial Health
| Debt / Equity | 35.77 |
| Current Ratio | 0.39 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ATLN | Atlantic International Corp. | $73M | 7.10 | -83.2% | |
| RPRX | Royalty Pharma plc | $26.0B | 24.39 | 3.83 | |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $11.7B | 217.89 | 16.92 | 8.4% |
| LQDA | Liquidia Corporation | $5.8B | 43.62 | 31.18 | 149.6% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.8B | 70.23 | 8.91 | 13.7% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | |||
| PBH | Prestige Consumer Healthcare Inc. | $2.2B | 13.05 | 1.16 |
Price Performance
| 1 month | +0.00% |
| 3 months | +63.54% |
| Year-to-date | -32.32% |
| 1 year | -73.68% |
| 3 years | -94.23% |
52-Week Range
| 52-week High | $5.25 |
| 52-week Low | $0.41 |
| Avg Volume (90d) | 7.2M |
Related companies: ASH.AX · CHZ.SI · CIRC · CWLPF · HQI · ILLR · IPDN
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of ATLN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks